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Plasmodium falciparum parasites are responsible for the major
global disease malaria, which results in >2 million deaths each
year. With the rise of drug-resistant malarial parasites, novel drug
targets and lead compounds are urgently required for the devel-
opment of new therapeutic strategies. Here, we address this
important problem by targeting the malarial neutral aminopepti-
dases that are involved in the terminal stages of hemoglobin
digestion and essential for the provision of amino acids used for
parasite growth and development within the erythrocyte. We
characterize the structure and substrate specificity of one such
aminopeptidase, PfA-M1, a validated drug target. The X-ray crystal
structure of PfA-M1 alone and in complex with the generic inhib-
itor, bestatin, and a phosphinate dipeptide analogue with potent
in vitro and in vivo antimalarial activity, hPheP[CH2]Phe, reveals
features within the protease active site that are critical to its
function as an aminopeptidase and can be exploited for drug
development. These results set the groundwork for the devel-
opment of antimalarial therapeutics that target the neutral
aminopeptidases of the parasite.
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There are 300–500 million cases of clinical malaria annually, and1.4–2.6 million deaths. Malaria is caused by apicomplexan
parasites of the genusPlasmodium, withPlasmodium falciparum the
most lethal of the 4 species that infect humans. Clinical manifes-
tations begin when parasites enter erythrocytes, and most antima-
laria drugs, such as chloroquine, exert their action by preventing the
parasite development within these cells (1). As a result of the rapid
spread of drug-resistant parasites, there is a constant need to
identify and validate new antimalarial targets.
Intraerythrocytic parasites have limited capacity for de novo
amino acid synthesis and rely on degradation of host hemoglobin
(Hb) to maintain protein metabolism and synthesis, and an
osmotically stable environment within the erythrocyte (1–4).
Within the erythrocytes, malaria parasites consume as much as
75% of the cellular Hb (1). Hb is initially degraded by the
concerted action of cysteine-, aspartyl-, and metallo-
endoproteases, and a dipeptidase (cathepsin C) within a diges-
tive vacuole (DV) to di- and tripeptide fragments (5, 6). These
fragments are suggested to be exported to the parasite cyto-
plasm, where further hydrolysis to release free amino acids takes
place [supporting information (SI) Fig. S1; see refs. 7 and 8].
The release of amino acids involves 2 metallo-exopeptidases:
an alanyl aminopeptidase, PfA-M1 (9, 10), and a leucine
aminopeptidase, PfA-M17 (7, 11, 12). We have demonstrated
that the aminopeptidase inhibitor bestatin, an antibiotic and
natural analogue of the dipeptide Phe-Leu derived from the
fungus Streptomyces olivoretticul, prevents P. falciparum ma-
laria growth in culture (13, 14). More recently, it was shown not
only that synthetic phosphinate dipeptide analogues that in-
hibit metallo-aminopeptidases prevented the growth of wild-
type and the chloroquine-resistant parasites in culture but also
that one compound, hPheP[CH2]Phe (termed compound 4,
Co4), reduced a murine infection of Plasmodium chabaudi
chabaudi by 92% compared with controls (15, 16). Impor-
tantly, Co4 was found to cause no toxicity in these in vivo
studies (16). Here, we functionally characterize PfA-M1 and
validate it as a target for the inhibitory activity of bestatin and
hPheP[CH2]Phe. We also present its 3D structure alone and
complexed with both of these inhibitors, which sets the ground-
work for the development of a previously undescribed class of
antimalarial drugs.
Results and Discussion
Substrate Specificity of the P. falciparum Alanyl Aminopeptidase
PfA-M1. The M1 alanyl aminopeptidase gene (MAL13P1.56) (9),
as annotated by PlasmoDB, is present in single copy and located
on chromosome 13 of P. falciparum. The gene is 3,257 bp in
length and encodes a protein, known as PfA-M1, of 1,085 aa and
126 kDa. The full-length amino acid sequence of PfA-M1
exhibits 70% sequence similarity with M1 aminopeptidase
orthologues of the various rodent malaria species (Plasmodium
berghei, P. chabaudi chabaudi, and Plasmodium yoelii); the
sequences are most divergent at the large nonconserved N-
terminal extension (194 aa), which contains 3 asparagine-rich
low-complexity regions (LCRs) and a putative transmembrane
domain (Fig. S2).
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Using peptide antisera, Florent et al. (9) and Florent and
coworkers (10), detected a 122-kDa PfA-M1 in membrane
fractions of malaria parasites. However, this membrane form
appeared to be further processed to smaller active soluble forms
of 96 and 68 kDa. In our studies, expression of the full-length
PfA-M1 was not successful, so a truncated form of the P.
falciparum M1 aminopeptidase (residues 195-1085) correlating
with the start of theM1 aminopeptidase of Escherichia coli PepN
was prepared (17, 18). The construct lacked the 3 asparagine-
rich LCRs and the putative transmembrane domain (Fig. S2) but
was successfully expressed in E. coli and extracted as a soluble
functional enzyme. The protein resolved as amajor band at100
kDa (predicted molecular mass 104.678 kDa) with a minor
N-terminally truncated breakdown product of 55 kDa on
reducing SDS/PAGE (Fig. S3).
The purified recombinant PfA-M1 (rPfA-M1) exhibited a
similar retention time on HPLC size analysis as the PfA-M1 in
soluble extracts of P. falciparum parasites, both eluting between
80 and 100 kDa (Fig. S3). In support of the studies by Florent et
al. (9), and Florent and coworkers (10), PfA-M1 antisera local-
ized the enzyme to the parasite cytosol (data not shown). Also,
P. falciparum D10 parasites transfected with a plasmid (pHTB-
PfA-M1-cmycB) carrying the truncated PfA-M1 gene expressed
and trafficked an 115-kDa product (Fig. 1A) to the parasite
cytosol (Fig. 1B). These transgenic parasites exhibited a 2.8-fold
higher level of PfA-M1 activity compared with D10 wild-type
parasites, showing that the transgene product was functionally
active within the parasite. Northern blotting experiments showed
that the PfA-M1 is expressed at all stages in the development of
the malaria parasites in the erythrocyte (Fig. 1C).
The rPfA-M1 protein displayed a broad specificity for amino
acids, demonstrated by its ability to cleave peptide bonds
involving hydrophobic, basic, and aromatic amino acids, which
is consistent with M1 aminopeptidases of E. coli PepN (17, 18)
and Salmonella typhimurium PepN (19). The most efficiently
cleaved P1 substrates were Leu (kcat/Km  4,607 M1s1), Ala
(kcat/Km  2,295 M1s1), Arg (kcat/Km  1,491 M1s1), and
Phe (kcat/Km  924 M1s1) (Table S1). However, proline was
a poor substrate with kcat/Km a least 1,000-fold less than Leu
(Table S1), consistent with the catalytic mechanism described
by Ito et al. (20), who suggest that 2 conserved glutamate residues
stabilize the reaction intermediate through the formation of
hydrogen bonds with the terminal amino group, NH3. The
presence of a proline in the P1 position may prevent such
interactions forming due to the constraints imposed by the
cyclized side chain. The rPfA-M1 protein did not cleave after the
acidic amino acids Glu and Asp, which is consistent with our
suggestion that another enzyme, a cytosolic M18 aspartyl ami-
nopeptidase, is responsible for the specific removal of these
residues from peptides (21).
The efficient cleavage of the amino acid Arg is of particular
interest, because this amino acid is not cleaved by the othermajor
malaria aminopeptidase, PfA-M17 (12). This observation facil-
itated the development of a specific assay for measuring PfA-M1
in malaria extracts. Thus, by using Arg as a substrate, we showed
that rPfA-M1 and native PfA-M1 activity within soluble extracts
of malaria parasites exhibited optimal activity at pH 7.0, with
20% activity below pH 6.0, which is consistent with a cytosolic
function for the enzyme (Fig. 1D) (12). Also, both rPfA-M1 and
native PfA-M1 activity depends on a divalent metal ion as metal
chelators (1 mM EDTA or o-phenanthroline) were found to
inhibit their activity. Collectively, the above data demonstrate
that despite lacking the N-terminal domain, rPfA-M1 exhibits
i ii iii iv
i ii iii iv
Fig. 1. Analysis of PfA-M1 expression and activity. (A) Western blot of transgenic parasites expressing the product of the inserted transgene encoding PfA-M1.
The blot was probed with a monoclonal anti-c-myc primary antibody followed by horseradish peroxidase-conjugated anti-mouse immunoglobulin antibodies
and visualized by enhanced chemiluminescence. (B) Indirect immunofluorescence of transgenic parasites stained with monoclonal anti c-myc primary antibody
followed by anti-mouse cy2. (i) Bright field; (ii) anti-c-myc antibody; (iii) anti-c-myc/nuclear stain merged; (iv) merge of i and iii. The data show that the PfA-M1
transgenic protein is localized to the parasite cytosol. (C) Northern blot analysis of stage-specific parasite RNA reveals that the endogenous PfA-M1 is expressed
by parasites at all developmental stages within the erythrocyte. Developmental stages are indicated at the top: R, ring stage parasites; ET, early trophozoite
parasites; LT, late trophozoite parasites; and S, schizont stage parasites. Size difference observed between trophozoite and ring/schizont is due to different
transcription initiation sites. (D) The pH optima for activity of rPfA-M1 (circles) and native PfA-M1 in soluble extracts of parasites (squares) measured by using
the fluorogenic peptides substrate H-Arg-NHMec.
2538  www.pnas.orgcgidoi10.1073pnas.0807398106 McGowan et al.
physicobiochemical characteristics identical to those of the
native soluble malaria PfA-M1 enzyme.
X-Ray Crystal Structure of rPfA-M1 Confirms Bacterial Aminopepti-
dase Fold. Outside malaria, PfA-M1 shows closest identity
(35%) to the bacterial M1 aminopeptidases, which do not
contain the extended N-terminal domain. We determined the
X-ray crystal structure rPfA-M1 to 2.1 Å (Table S2). The
structure confirmed that rPfA-M1 adopts the bacterial amino-
peptidase N-fold (20, 22, 23), and comprises 26 -helices and 7
-sheets divided into 4 domains (Fig. 2A). The catalytic domain
II (residues 392–649) adopts a thermolysin-like fold and con-
tains the active site, incorporating the zinc-binding motif
H496EYFHX17KE519 and the well-conserved G490AMEN motif
involved in substrate recognition (20, 22, 23). The catalytic zinc
ion is coordinated by N2 atoms of His496 and His500, the
carboxyl O atom of Glu519, and a water molecule that acts as the
nucleophile that attacks the carbonyl carbon of the substrate
(20). This water molecule forms a slightly longer metallo-bond
with the zinc ion and is also coordinated by Glu497 and Glu463.
It is not clear what the catalytic base of the reaction is, but the
structure suggests that it may be the Glu497 residue.
Inspection of the molecular surface of PfA-M1 reveals 2
openings to the active site cavity. The first opening (N-terminal
channel) comprises a shallow 8-Å-long groove at the junction of
domains I and IV (Fig. 2B). The second and larger opening
(C-terminal channel) is formed by the C-terminal domain IV,
which comprises 8 pairs of -helices arranged in 2 layers to form
a cone-shaped superhelical structure. This domain interacts with
the catalytic domain II and contains an 30-Å-long channel
leading toward the active site (Fig. 2C). At the entrance, a helix
(14) with a 90° bend confines the pore size to 13-Å diameter.
The rPfA-M1 Has a Buried Active Site That Does Not Require Confor-
mational Change to Bind Substrate.Bestatin is an antibiotic originally
isolated from filtrates of the fungus S. olivoretticul, but is now
available in synthetic form (24). Its structure N-[(2S,3R)-3-amino-
2-hydroxy-4-phenylbutanoyl]-L-leucine is an analogue of the dipep-
tide Phe-Leu. Thus, bestatin is a competitive inhibitor of many
metallo-aminopeptidases (24). Accordingly, kinetic studies per-
formedwith rPfA-M1 revealed that bestatin is an effective inhibitor
of rPfA-M1, with an inhibitory constant Ki  478.2 nM.
More recently, a new class of metallo-aminopeptidase in-
hibitors, phosphinate dipeptide analogues, were designed by
using a computer-aided approach by Grembecka et al. (15); 1
of these hPheP[CH2]Phe, Co4, exhibited more potent inhibi-
tion of rPfA-M1 (Ki  79 nM) than bestatin. Both bestatin and
Co4 had similar killing activity against malaria parasites in culture;
IC50 bestatin range 8–14 M and Co4 is 24–62 M (Fig. 3).
However, bestatin only showed low-level (33%) antimalarial activ-
ity in murine (P. c. chabaudi) models, whereas Co4 was much more
potent and reduced infection by 92% compared with controls (16).
To elucidate the mechanism by which bestatin and Co4 bound to
Fig. 2. The structure of rPfA-M1. (A) Diagram of unbound rPfA-M1 colored by domain: I (blue), II (green), III (yellow), and IV (red). (B and C) Molecular surface
of PfA-M1 (colored as in A) showing small (B) and large (C) openings to active site (active site cavity shown in magenta).
Fig. 3. The inhibitory effect of the aminopeptidase inhibitor bestatin
(squares), and Co4 (triangles) on P. falciparum clone 3D7 growth in culture
compared with parasites grown in the absence of inhibitor (circles). Data are
presented as mean  SD of 3 independent, triplicate experiments. Parasites
grown in the presence of bestatin or Co4 for 24 h exhibit cellular damage and
stunted development compared with control parasites grown in the absence
of drug (Inset).
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the active site of rPfA-M1, we determined the X-ray crystal
structure of rPfA-M1 complexed to each inhibitor to 1.65 and
2.0 Å, respectively (Table S2). Given that the active site of the
enzyme is buried in the middle of the protein, we were particularly
interested in understanding whether conformational change is
required for substrate/inhibitor entry. Interestingly, comparison of
the unbound and ligand-bound structures revealed that the enzyme
does not undergo any global conformational rearrangements on
binding either inhibitor [rmsd of 0.14 (bestatin) and 0.16 Å
(Co4)890 C atoms]. The omit electron density of ligands within
the active site was well defined (Fig. 4), and the dipeptide analogues
slot neatly into the large catalytic cavity without causing any major
alterations to active site residues.
In E. coli aminopeptidase N protein Met454, positioned im-
mediately preceding the GAMEN exopeptidase motif, is postu-
lated to function as a cushion to accept substrates (20), altering
the size of the active site pocket. This residue is conserved in
bacterial aminopeptidases; however, the equivalent position
(469) in eukaryote M1 aminopeptidases is commonly a smaller
valine or alanine residue. We noted no movement of the
rPfA-M1 Val469 residue to accommodate either the bestatin or
Co4 molecule. Indeed, only 2 residues showed significant move-
ment after ligand binding, the Glu526 side chain that moves away
from the active site, removing what would otherwise form a close
contact with P1 position of either inhibitor (Leu moiety of
bestatin or the Phe ring of Co4). However, in the unbound form
of rPfA-M1, the Met1034 residue adopts 2 alternative conforma-
tions in the ligand-bound structures, this side chain adopts a
single conformation and forms packing interactions with the
inhibitor moieties (P1 position).
The lack of any large scale conformational changes in the bound
structure suggests that it is unlikely a conformational change is
required for active site access. Indeed, initial attempts to obtain
data from a ligand-bound complex involved soaking the inhibitor
into rPfA-M1 crystals. This procedure caused no deterioration of
crystal quality (however, it did result in variable occupancy of the
active site, hence cocrystallization was used), also indicating that it
is unlikely that large-scale rearrangements of the protein molecules
are required for substrate/inhibitor binding. Therefore, we suggest
that the active site of this monomeric aminopeptidase is buried,
substrate access is achieved by means of the C-terminal domain
vortex, and that control of substrate hydrolysis can be achieved, and
depends on, the size of this channel.
Both inhibitors primarily interact with the enzyme through a
pentahedral coordination with the catalytic zinc ion (Fig. 4).
Aside from bonds with His496, His500, and Glu519, the hydroxyl
group (O2) and the carbonyl group (O3) of bestatin and the
central phosphoryl O atoms of Co4 are coordinated to the zinc
ion (Fig. S4). Pentahedral zinc coordination, rather than the
tetrahedral geometry observed in the unbound structure, is
required for the transition state of the enzyme that exists after
the nucleophilic attack at the carbonyl carbon of the substrate.
The bestatin carbonyl carbon (O3) and the Co4 central phos-
phoryl O atoms (O3 and O4; Fig. S4) also form hydrogen bonds
with the side chain of Tyr580, stabilizing this reaction interme-
diate. A cis-peptide (Glu319-Ala320) allows the side chain of
Glu319 to extend into the active site, where it forms a hydrogen
bond with the N2 atom of bestatin and the amino group (NH2)
of Co4 (Fig. 4). The GAMEN recognition motif residues also
contribute hydrogen bonds to ligand binding with the side chain
of Glu463 and main-chain amide of Gly460, with both inhibitors
(Fig. 4). Bestatin also forms a hydrogen bond with the main-
chain amide of Ala461 (Table S3). When bound, Co4 resides in
an extended conformation (11 Å from Phe-ring centroids) and
has a total contact area of 19.9Å2 (compared with bestatin total
buried surface area of 17.7 Å2). The 2 Phe rings of Co4 form
favorable hydrophobic interactions; the Phe ring at P1 position
(C1-C6, Fig. S4) packs against side-chains of residues Arg489,
Thr492, and Val493, whereas the Phe ring at position P1 (C10-C16,
Fig. S4) forms hydrophobic contacts with side chains of Gln317,
Val459, Met462, Tyr575, and Met1034. In bestatin, the Leu moiety
is f lanked by Val459 and Thr492; 2 water molecules also coordi-
nate the O1 atom (bestatin) with the N atoms of Arg489. The
Phe-like amino acid is cushioned by hydrophobic interactions
with Gln317, Met462, Tyr575, and Met1034. In total, bestatin makes
8 hydrogen bonds with the active site, whereas Co4 forms only
6 hydrogen bonds (Table S3). However, Co4 is further stabilized
by 10 residues contributing to its hydrophobic packing within in
the active site core in contrast to bestatin, which has only 7 such
interactions with only 1 residue (Thr492), contributing to the
stability of the leucyl moiety in the P1 position.
Bestatin is a natural analogue of the dipeptide Phe-Leu, but
is a much weaker inhibitor of PfA-M1 than Co4. When analyzing
the active site contacts of the 2 ligands, a possible distinction
between potency to Co4 of bestatin may be due to a lack of
contacts made by the leucyl side chain of bestatin, leaving a open
hydrophobic cleft that is filled when Co4 is bound. Interestingly,
the phosphinate dipeptide hPheP[CH2]Gly (Co2) is a signifi-
cantly poorer inhibitor than Co4 [having a 13-fold greater Ki of
1,030.0 nM than Co4 (hPheP[CH2]Phe)] (16). We suggest that
this reduced potency is probably also due to the lack of contacts
at the P1 position within this large active-site cavity. Because of
its high Ki, compound hPheP[CH2]Gly does not exhibit antima-
larial activity in vitro. However, these data clearly highlight the
impact such ligand-binding analysis may have for structure-based
drug design in conjunction with biological analysis.
Fig. 4. Stereo diagram of inhibitors binding to active site of rPfA-M1. (A)
1.65-Å rPfA-M1-BES and (B) 2.0-Å rPfA-M1-Co4 active site showing inhibitors
bound in the active site. Inhibitors (BES/Co4) are colored in magenta. Carbon
atoms of residues are colored by domain: I (blue), II (green), IV (red), and Zn is
shown as black sphere.Watermolecules are shown as blue spheres. Hydrogen
bonds are indicated (dashed lines). Electron density is a composite omit map
contoured at 1.0  calculated by using amodel containing only PfA-M1 atoms
(no zinc, ligand, or water was included in the calculation).
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The active site of PfA-M1 is buried deep in the structure,
providing a solution to the problem of controlling appropriate
substrate entry, as well as preventing hydrolysis of unwanted
substrates. By comparison with the available bacterial
aminopeptidases structures (20, 22, 23), PfA-M1 can, thus, be
considered to adopt a ‘‘closed’’ conformation. Interestingly,
structural studies on the homologous tricorn-interacting factor 3,
F3, reveals this protease undergoes a substantial conformational
changes on substrate entry, where domain IV swings away from
domain II, exposing the active site. However, for the aminopep-
tidase N structures available, including PfA-M1, there is no
movement of the C-terminal domain noted, even in the presence
of inhibitors. We argue that in PfA-M1, the large C-terminal
channel functions to permit substrate entry whereby Hb-derived
peptides access the buried active site leaving the smaller sized
opening for exit of released amino acids. A maximal pore size of
10 Å has been proposed to serve as the entry point in other
multimeric proteases structures (22, 25); here, we suggest that for
such an opening is sufficient to allow access to the buried active
site of this monomeric protease.
Given our detailed knowledge of the active site of the PfA-M1
enzyme, high-throughput screening of chemical libraries followed
by medicinal chemistry would allow the development of additional
lead antimalarial compounds. The static nature of this family of
proteases allows the opportunity for a 2-fold approach to rational
drug design; discovery of lead compounds that bind to and irre-
versibly block the active site, and/or compounds that block egress of
digestion products by occluding the N-terminal channel, both
essentially trapping the molecule in an inactive state.
Conclusions
There is a paucity of new antimalarial drugs entering the
development pipeline. Our report of the unique active site
structure of PfA-M1, in complex with the antimalarial inhibitors
bestatin and Co4, provides the groundwork for the de novo
discovery of a previously unrecognized class of antimalarials by
using high-throughput chemical screening and medicinal chem-
istry. Co4 also inhibits the second important neutral aminopep-
tidase of malaria, PfA-M17 (12, 26), creating the possibility of
developing a 2-target or combination therapy that would be
more resilient to the emergence of drug-resistant malaria
parasites.
Materials and Methods
Parasite Preparation. P. falciparum clone D10 was cultured as described (27).
For experiments investigating the stage specific expression of PfA-M1, para-
siteswere synchronizedbyusing2 roundsof sorbitol treatment (28), and stage
specific parasites harvested at ring, trophozoite, and schizont stage. Details of
parasites, and methods of immunoblotting, Northern blotting, and transfec-
tion can be found in SI Methods.
Enzymatic Analysis. Aminopeptidase activity was determined by measuring
the release of the fluorogenic leaving group, 7-amino-4-methyl-coumarin
(NHMec) from the fluorogenic peptide substrates (SI Methods).
In Vitro Sensitivity of P. falciparum Malaria Parasites to Aminopeptidase
Inhibitors. The in vitro sensitivity of each parasite population to bestatin, Co4
and Co2 was determined by using [3H]-hypoxanthine incorporation (for fur-
ther details see SI Methods) (29). IC50 values were determined by linear
interpolation of inhibition curves (SI Methods).
Crystallization, X-Ray Data Collection, Structure Determination, and Refine-
ment. A truncated form of PfA-M1 (residues 195-1085, rPfA-M1) was purified
from E. coli (SIMethods); rPfA-M1 at 5mg/mL in 50mMHepes pH 8.5; 300mM
NaCl 5% (vol/vol) glycerolwas crystallized in 22% (vol/vol) polyethylene glycol
8000, 10% (vol/vol) glycerol, 0.1 M Tris (pH 8.5), and 0.2 M MgCl2. Crystals of
the ligand bound rPfA-M1 complexes were obtained by cocrystallization
under similar conditions in the presence of 1 mM ligand. The diffraction data
for the unbound, bestatin-bound, and Co4-bound protease were collected to
2.1-, 1.65-, and 2.0-Å resolution, respectively (Table S2). Crystallographic
analysis was performed by using CCP4i (30–33). The structurewas determined
by using the program PHASER (34) (using 2GTQ.pdb as a search probe; see ref.
23). Refinementwas performedbyusingREFMAC (35). Allmodel buildingwas
done by using COOT (for further crystallization details, see SI Methods) (36).
ACKNOWLEDGMENTS. J.C.W. is an Australian Research Council (ARC) Feder-
ation Fellow; A.M.B. is a National Health and Medical Research Council
(NHMRC) Senior Research Fellow; and C.J.P. is a NHMRC Training (Peter
Doherty) Fellow. J.P.D., K.R.T., and D.G. are supported by the ARC Discovery
Project Grant DP0666128; K.R.T. and D.G. by the NHMRC Program Grant
290208 and by generous donation from Mark Nicholson, Alice Hill, and the
Tudor Foundation; and T.S-A. by a University of Queensland Postdoctoral
Fellowship and a Ramaciotti Development grant.
1. Rosenthal PJ (2003) Antimalarial drug discovery: Old and new approaches. J Exp Biol
206:3735–3744.
2. DivoAA,Geary TG, Jensen JB (1985)Oxygen- and time-dependent effects of antibiotics
and selected mitochondrial inhibitors on Plasmodium falciparum in culture. Antimi-
crob Agents Chemother 27:21–27.
3. Lew VL, Macdonald L, Ginsburg H, Krugliak M, Tiffert T (2004) Excess hemoglobin
digestion by malaria parasites: A strategy to prevent premature host cell lysis. Blood
Cells Mol Dis 32:353–359.
4. Liu J, Istvan ES, Gluzman IY, Gross J, Goldberg DE (2006) Plasmodium falciparum
ensures its amino acid supply with multiple acquisition pathways and redundant
proteolytic enzyme systems. Proc Natl Acad Sci USA 103:8840–8845.
5. Klemba M, Gluzman I, Goldberg DE (2004) A Plasmodium falciparum dipeptidyl
aminopeptidase I participates in vacuolar hemoglobin degradation. J Biol Chem
279:43000–43007.
6. Rosenthal PJ (2002) Hydrolysis of erythrocyte proteins by proteases of malaria para-
sites. Curr Opin Hematol 9:140–145.
7. Curley GP, et al. (1994) Aminopeptidases from Plasmodium falciparum, Plasmodium
chabaudi chabaudi and Plasmodium berghei. J Eukaryot Microbiol 41:119–123.
8. Kolakovich KA, Gluzman IY, Duffin KL, Goldberg DE (1997) Generation of hemoglobin
peptides in the acidic digestive vacuole of Plasmodium falciparum implicates peptide
transport in amino acid production. Mol Biochem Parasitol 87:123–135.
9. Florent I,et al. (1998)APlasmodiumfalciparumaminopeptidasegenebelonging to the
M1 family of zinc-metallopeptidases is expressed in erythrocytic stages.Mol Biochem
Parasitol 97:149–160.
10. Allary M, Schrevel J, Florent I (2002) Properties, stage-dependent expression and
localization of Plasmodium falciparum M1 family zinc-aminopeptidase. Parasitol-
ogy 125:1–10.
11. Gavigan CS, Dalton JP, Bell A (2001) The role of aminopeptidases in hemoglobin
degradationinPlasmodiumfalciparum-infectederythrocytes.MolBiochemParasitol117:37–
48.
12. Stack CM, et al. (2007) Characterization of the Plasmodium falciparum M17 leucyl
aminopeptidase. A protease involved in amino acid regulation with potential for
antimalarial drug development. J Biol Chem 282:2069–2080.
13. Gavigan CS, Machado SG, Dalton JP, Bell A (2001) Analysis of antimalarial synergy
between bestatin and endoprotease inhibitors using statistical response-surfacemod-
elling. Antimicrob Agents Chemother 45:3175–3181.
14. Nankya-Kitaka MF, Curley GP, Gavigan CS, Bell A, Dalton JP (1998) Plasmodium
chabaudi chabaudi and P. falciparum: Inhibition of aminopeptidase and parasite
growth by bestatin and nitrobestatin. Parasitol Res 84:552–558.
15. Grembecka J, Mucha A, Cierpicki T, Kafarski P (2003) The most potent organophos-
phorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and
activity. J Med Chem 46:2641–2655.
16. Skinner-Adams TS, et al. (2007) Identification of phosphinate dipeptide analog inhib-
itors directed against the Plasmodium falciparumM17 leucine aminopeptidase as lead
antimalarial compounds. J Med Chem 50:6024–6031.
17. Chandu D, Nandi D (2003) PepN is the major aminopeptidase in Escherichia coli:
Insights on substrate specificity and role during sodium-salicylate-induced stress. Mi-
crobiology 149:3437–3447.
18. Golich FC, Han M, Crowder MW (2006) Over-expression, purification, and charac-
terization of aminopeptidase N from Escherichia coli. Protein Expr Purif 47:634–
639.
19. Kumar A, Nandi D (2007) Characterization and role of peptidase N from Salmonella
enterica serovar Typhimurium. Biochem Biophys Res Commun 353:706–712.
20. Ito K, et al. (2006) Crystal structure of aminopeptidase N (proteobacteria alanyl
aminopeptidase) from Escherichia coli and conformational change of methionine 260
involved in substrate recognition. J Biol Chem 281:33664–33676.
21. Teuscher F, et al. (2007) The M18 aspartyl aminopeptidase of the human malaria
parasite Plasmodium falciparum. J Biol Chem 282:30817–30826.
22. Addlagatta A, Gay L, Matthews BW (2006) Structure of aminopeptidase N from
Escherichia coli suggests a compartmentalized, gated active site. Proc Natl Acad Sci
USA 103:13339–13344.
23. Nocek B, Mulligan R, Bargassa M, Collart F, Joachimiak A (2007) Crystal structure of
aminopeptidase N from human pathogen Neisseria meningitidis. Proteins 273:273–
279.
24. Scornik OA, Botbol V (2001) Bestatin as an experimental tool in mammals. Curr Drug
Metab 2:67–85.
McGowan et al. PNAS  February 24, 2009  vol. 106  no. 8  2541
BI
O
CH
EM
IS
TR
Y
25. Russo S, Baumann U (2004) Crystal structure of a dodecameric tetrahedral-shaped
aminopeptidase. J Biol Chem 279:51275–51281.
26. Gardiner DL, Trenholme KR, Skinner-Adams TS, Stack CM, Dalton JP (2006) Overex-
pression of leucyl aminopeptidase in Plasmodium falciparum parasites. Target for the
antimalarial activity of bestatin. J Biol Chem 281:1741–1745.
27. Trager W, Jensen JB (1976) Human malaria parasites in continuous culture. Science
193:673–675.
28. Lambros C, Vanderburg JP (1979) Synchronization of Plasmodium falciparum eryth-
rocytic stages in culture. J Parasitol 65:418–420.
29. Geary TG, Delaney EJ, Klotz IM, Jensen JB (1983) Inhibition of the growth of Plasmo-
dium falciparum in vitro by covalent modification of hemoglobin. Mol Biochem
Parasitol 9:59–72.
30. Leslie AGW (1992) Joint CCP4  ESF-EAMCB Newslett Prot Crystallogr (Daresbury
Laboratory, Warrington, UK), 26.
31. Evans P (2006) Scaling and assessment of data quality. Acta Crystallogr D
62:72–82.
32. Potterton E, Briggs P, TurkenburgM, Dodson E (2003) A graphical user interface to the
CCP4 program suite. Acta Crystallogr D 59:1131–1137.
33. CCP4 (1994) The CCP4 suite: Programs for protein crystallography. Acta Crystallogr D
50:760–763.
34. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ (2005) Likelihood-enhanced fast
translation functions. Acta Crystallogr D 61:458–464.
35. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement ofmacromolecular structures
by the maximum-likelihood method. Acta Crystallogr D 53:240–255.
36. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta
Crystallogr D 60:2126–2132.
37. Davis IW, et al. (2007) Molprobity: All-atom contacts and structure validation for
proteins and nucleic acids. Nucleic Acids Res 35:W375–W383.
2542  www.pnas.orgcgidoi10.1073pnas.0807398106 McGowan et al.
Supporting Information
McGowan et al. 10.1073/pnas.0807398106
SI Methods
Parasites and Preparation of Parasite Extract. Plasmodium falcipa-
rum clone D10 was cultured as described (1). For experiments
investigating the stage-specific expression of PfA-M1, parasites
were synchronized by using 2 rounds of sorbitol treatment (2),
and stage-specific parasites were harvested at ring, trophozoite,
and schizont stage.
The P. falciparum M1 Alanyl Aminopeptidase Gene. Because of the
high AT-richness of genes encoding malarial proteins PfA-M1
was chemically synthesized by GeneArt using codons for opti-
mized gene expression in the yeast Pichia pastoris. Potential
N-linked glycosylation sites were removed during gene synthesis
by replacing the asparagine of all Asn-Xaa-(Thr/Ser) motifs with
glutamine (Gln, Q). However, expression with the codon opti-
mized PfA-M1 in P. pastoris was unsuccessful; therefore, we
turned to Escherichia coli as the expression host. In this host,
expression of the full-length gene did not result in a functionally-
active enzyme and, therefore, a truncated form of the P.
falciparum M1 aminopeptidase (residues 195-1085, rPfA-M1;
see Fig. 1), which removed N-terminal low-complexity regions
and a putative transmembrane region was prepared by PCR
amplification using the synthesized gene as a template followed
by directional cloning into the bacterial expression vector
pTrcHis2B (Invitrogen). The primers used were M1 forward
5-CTGCAGAACCAAAGATCCAC-3, and M1 reverse
5-GGTACCTCAATGATGATGATGATGATGTGGGCCCA-
ACTTGTTTGT-3. Unique PstI and KpnI sites (underlined)
were introduced at the 5 and 3 ends of the amplified product.
A C-terminal His-tag was introduced into the M1 reverse primer
(italics). The construct housing the truncated PfA-M1 gene was
verified by DNA sequencing. The verified construct was then
transformed into competent BL21 cells. Expression was carried
out as per the supplier’s instructions (Invitrogen).
Purification and Molecular Analysis of Recombinant M1 Alanine Ami-
nopeptidase (rPfA-M1).The rPfA-M1 was purified from BL21 cells
by using a Ni NTA-agarose column as previously described (3).
Native PfA-M1 from soluble extracts of malaria parasites (80%
trophozoites) was prepared as described previously (3). Size
analysis was performed by (i) SDS/12% PAGE analysis, and (ii)
gel-permeation chromatography using a Amersham Pharmacia
Biotech Smart System HPLC equipped with a Superdex-200
gel-filtration column. The proteins (40 L containing 10–20 g
of protein) were passed through the column at a flow rate of 40
L/min, and fractions were analyzed for aminopeptidolytic
activity toward the fluorogenic substrate H-Arg-7-amino-4-
methylcoumarin (NHMec) as described below. Separation of the
molecular-size standards apoferritin (440 kDa), -amylase (232
kDa), BSA (67 kDa), and carbonic anhydrase (29 kDa) was
monitored by A280.
Enzymatic Analysis. Aminopeptidase activity was determined by
measuring the release of the fluorogenic leaving group, NHMec,
from the fluorogenic peptide substrates H-Leu-NHMec, H-Ala-
NHMec, H-Arg-NHMec, H-Met-NHMec, H-Phe-NHMec, H-
Gly-NHMec, H-Val-NHMec, H-Ile-NHMec H-Glu-NHMec, H-
Asp-NHMec, and H-Pro-NHMec. Reactions were carried out in
96-well microtiter plates (200 L total volume, 30 min, 37 °C) by
using a spectrofluorimeter (Bio-Tek KC4), with excitation at 370
nm and emission at 460 nm. Enzyme was first added to 50 mM
TrisHCl, pH 8.0, before the addition of 10 M H-Leu-NHMec.
Initial rates were obtained at 37 °C over a range of substrate
concentrations spanning Km (0.2–500 M), and at fixed enzyme
concentrations in 50 mM TrisHCl, pH 8.0. Experiments to
characterize the pH optimum and metal dependency of the
rPfAM1 were carried out by using various buffers over the pH
range 3–10, and in the presence or absence of metal chelators
EDTA and o-phenathroline as described (3).
Northern Blotting. Total RNA was extracted and Northern blot-
ting was performed essentially as described by Kyes et al. (4) with
the following modifications: 100-L pellet volumes of infected
red blood cells were collected from cultures at5% parasitemia,
lysed, and stored in TRIzol (Invitrogen). Samples were sepa-
rated on a 1% TBE agarose gel containing 10 mM guanidine
thiocyanate (Sigma–Aldrich), soaked in 50 mM NaOH for 30
min, and transferred onto a Hybond Nmembrane (Amersham
Biosciences).
Blots were probed with a 1,500-bp PCR product amplified
from a full-length PfA-M1 pGem clone by using primers PfA-
M1IntF (TACAATGGGCTTTAGAATGTC), and PfA-
M1IntR (AATTCATCATCTTTTGA). This product was la-
beled with [-32P]dCTP by random priming by using a
Decaprime II kit (Ambion). The probe was hybridized overnight
at 40 °C in a hybridization buffer containing formamide (North-
ern Max; Ambion). The filter was washed once at low stringency
and twice at high stringency (Northern Max; Ambion), then
exposed overnight to Super Rx Medical X-Ray film (Fuji), and
developed by using a Kodak X-Omat 3000RA processor
(Kodak).
Immunoblotting. Parasite protein fractions were extracted by
using 0.03% saponin (Sigma–Aldrich) and prepared as described
previously (5). SDS/PAGE was performed by using 10% acryl-
amide gels and run on Miniprotein II rigs (BioRad). Equal
loading was estimated by using the Bradford method (6), and by
staining gels with Coomassie Brilliant Blue (Bio-Rad) with
protein proportions visually estimated.
Protein was transferred onto Hybond C membranes (Am-
ersham Biosciences), which were blocked in 5% skim-milk
powder for 1 h at 37 °C or overnight at 4 °C. Anti-c-myc
(Sigma–Aldrich) were used as primary antibody to label trans-
genic PfA-M1 protein at a 1/3,000 dilution. The secondary
antibody was an anti-mouse IgG (Chemicon) used at a dilution
of 1/5,000. Blots were incubated with ECL Detection Reagents
(Amersham Biosciences), with exposure times ranging from 5 to
10 min.
In Vitro Sensitivity of P. falciparum Malaria Parasites to Aminopep-
tidase Inhibitors. The in vitro sensitivity of P. falciparum (3D7)
parasites to bestatin, Co4 (hPheP[CH2]Phe), and Co2
hPheP[CH2]Gly was determined by using [3H]hypoxanthine
incorporation (7). Briefly, serial dilutions of each inhibitor were
prepared in culture media (0.2–200 M) and added with [3H]hy-
poxanthine (0.5 Ci per well) to asynchronous cultures. After a
48-h incubation, the amount of [3H]hypoxanthine incorporation
was measured and IC50 values were determined by linear inter-
polation of inhibition curves (8). Each assay was performed in
triplicate on at least 2 separate occasions.
Crystallization, X-Ray Data Collection, Structure Determination, and
Refinement. Before crystallization, the purified rPfA-M1 enzyme
was dialyzed against gel filtration buffer [50 mMHepes (pH 8.5)
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300 mM NaCl, 5% (vol/vol) glycerol] before size-exclusion
chromatography using a Superdex S200 10/30 column and con-
centrated to 5 mg/mL. The crystals were grown by using the
hanging drop vapor diffusion method, with 1:1 (vol/vol) ratio of
protein to mother liquor (0.5 mL well volume). The crystals
appeared overnight in 22% (vol/vol) polyethylene glycol 8000,
10% (vol/vol) glycerol, 0.1 M Tris (pH 8.5), and 0.2 MMgCl2 and
reached full size in 3 days. Crystals of the rPfA-M1-Co4 and
rPfA-M1-bestatin complex were obtained by cocrystallization
under similar conditions in the presence of the ligand at 1 mM.
Crystals were dehydrated against reservoir buffer with 15%
(vol/vol) glycerol for 16 h. Crystals were equilibrated for 5 min
in reservoir buffer in the presence of 20% (vol/vol) glycerol.
Cryoannealing was performed 3 times by blocking the cryo-
stream (100 K) for 5 sec. Cryoannealing substantially improved
the diffraction quality observed. Crystal quality was variable and
a large number had to be screened.
Data were collected at 100 K by using both in-house and
synchrotron radiation. The diffraction data for the ligand-free,
Co4-bound, and bestatin-bound protease were collected to 2.1-,
2.0-, and 1.65-Å resolution, respectively. Diffraction images were
processed by using MOSFLM (9) and SCALA (10) from the
CCP4 suite (11); 5% of each dataset was flagged for calculation
of Rfree (12) with neither a  nor a low-resolution cut-off applied
to the data. A summary of statistics is provided in Table S2.
Subsequent crystallographic and structural analysis was per-
formed by using the CCP4i interface (13) to the CCP4 suite (11),
unless stated otherwise.
Structure solution preceded by using the molecular replace-
ment method and the program PHASER (14). A search model
was constructed from the crystal structure of aminopeptidase N
from Neisseria meningitides (PDB ID 2GTQ), the closest struc-
tural homolog identified by using the FFAS server (15). A
‘‘mixed’’ model, consisting of conserved side chains (all other
non-alanine/glycine residues truncated at C atom), was then
created by using the SCRWL server (15). A single clear peak in
both the rotation and translation functions was evident with 1
PfA-M1 monomer placed in the asymmetric unit. Unbiased (Fo
 Fc) density in initial electron density maps and initial refine-
ment cycles indicated that this solution was correct.
Maximum likelihood refinement using REFMAC (16), incor-
porating translation, liberation, and screw-rotation displacement
(TLS) refinement was carried out, by using a bulk solvent
correction (Babinet model with mask). Building was guided by
manual inspection of the model and Rfree. Simulated annealing
composite omit maps were generated by using CNS (17) omitting
5% of the model. All model building and structural validation
were done by using COOT (18). Water molecules were added to
the model by using ARP/wARP (19) when the Rfree reached
25%. Solvent molecules were retained only if they had accept-
able hydrogen-bonding geometry contacts of 2.5–3.5 Å with
protein atoms or with existing solvent, and were in good 2Fo 
Fc and Fo  Fc electron density.
PyMOL was used to produce all structural representations
(www.pymol.org). Hydrogen bonds (excluding water-mediated
bonds), were calculated by using the CONTACT (11). The
atomic coordinates and structure factors have been deposited in
the ProteinData Bank, www.rcsb.org (PDB ID codes 3EBG.pdb;
3EBH.pdb; and 3EBI.pdb).
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Fig. S1. Aminopeptidases PfA-M1 and PfA-M17 release amino acids from dipeptides that are transported from the digestive vacuole, where hemoglobin
digestion is initiated by various proteases.
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Fig. S2. Alignment of Plasmodium species M1 neutral aminopeptidases. Sequence alignment was prepared by using ClustalW and Espript. Identical residues
are highlighted in red and conservatively substituted amino acids are written in red. The Plasmodium species are listed on the left. Putative transmembrane
domain is boxed in green and asparagine-rich low complexity regions are located within black hashed boxes. The GAMEN substrate recognition motif is boxed
in solid black lines and the zinc binding motif is underlined with catalytic residues indicated (asterisk). The first amino acid of the truncated rPfA-M1 that was
successfully purified from E. coli is circled.
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Fig. S3. (A) Purification of rPfA-M1 by Ni-NTA-agarose affinity chromatography. Lane 1, bacterial extracts; lane 2, unbound protein; lane 3, purified rPfA-M1.
(B) Size separation of rPfA-M1 (0.04 mg/mL) and parasite soluble extracts (0.05 mg/mL) on a Superdex-200 column.
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Fig. S4. Binding of inhibitors to active site of rPfA-M1. (A) The 1.65-Å rPfA-M1-BES and (B) 2.0 Å rPfA-M1-Co4 active site showing inhibitors bound in the active
site. Carbon atoms of inhibitors (BES/Co4) are colored in gray and atom numbers are indicated. Carbon atoms of PfA-M1 residues are colored by domain: I (blue),
II (green), IV (red), and Zn shown as black sphere. Water molecules are shown as blue spheres. Hydrogen bonds are indicated (dashed lines).
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Table S1. Comparison of specificity constants for various N-terminal amino acids for rPfA-M1 at pH 7.5
Substrate kcat, s1 Km, M kcat/Km, M1s1 Abundance in human Hb, %
H-Leu-NHmec 1.52 329.9 4,607 12.46
H-Ala-NHmec 2.04 888.9 2,295 12.46
H-Arg-NHmec 1.07 717.4 1,491 2.08
H-Phe-NHmec 0.18 194.8 924 5.19
H-Gly-NHmec 0.116 348.6 333 6.92
H-Val-NHmec 0.036 1,068.1 34 10.73
H-Ile-NHmec 0.040 1,706 23 0
H-Pro-NHmec 0.0032 734.4 4 4.84
NHMec, 7-amino-4-methylcoumarin.
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Table S2. Data collection and refinement statistics
rPfA-M1 rPfA-M1-Co4 rPfA-M1-bestatin
Data collection
Space group P212121 P212121 P212121
Cell dimensions, Å a  75.7, b  108.7, c  118.4 a  75.9, b  108.6, c  118.3 a  75.7, b  108.6, c
 118.0
Resolution, Å 34.99–2.1 (2.21–2.1) 28.61–2.0 (2.11–2.0) 46.5–1.65 (1.74–1.65)
Total no. of observations 289,352 432,263 440,194
No. of unique
observations
56,863 60,523 95,094
Multiplicity 5.1 (3.8) 7.1 (5.5) 4.6 (4.1)
Data completeness, % 98.7 (94.0) 91.0 (77.5) 81.5 (68.1)
I/ I 16.7 (2.8) 22.0 (3.0) 18.3 (2.8)
Rpim, %* 4.2 (21.3) 3.0 (24.5) 2.9 (22.0)
Structure refinement
No. of nonhydrogen atoms
Protein 7,233 7,332 7,337
Solvent 762 739 835
Ligand — 26 23
Rfree, % 22.0 22.1 20.2
Rcryst, % 17.0 17.5 17.7
rms deviations from ideality
Bond lengths, Å 0.010 0.009 0.006
Bond angles, ° 1.13 1.33 0.97
Ramachandran plot
Favored, % 98.0 98.2 98.4
Allowed, % 100 100 100
B factors, Å2
Mean main chain 21.8 17.4 15.4
Mean side chain 22.6 19.8 18.2
Mean ligand — 23.5 18.2
Mean water molecule 30.8 33.3 29.7
rmsd bonded B values
Main chain 0.48 0.77 0.57
Side chain 1.1 2.3 1.9
MolProbity score (ref. 20) 1.38 (99th percentile†) 1.45 (98th percentile†) 1.24 (98th percentile‡)
Values in parentheses refer to the highest-resolution shell.
*Agreement between intensities of repeated measurements of the same reflections and can be defined as 	(Ih,i Ih)/	 Ih,i, where Ih,i are individual values and
Ih is the mean value of the intensity of reflection h.
†N  12,522, 1.75 Å (ref. 20).
‡N  9,033, 1.4–1.9 Å (ref. 20).
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Table S3. The rPfA-M1–ligand interactions
Metal core or protein ligand Bestatin atom Co4 atom Type of bond
Metal
Zn2 rPfA-M1 His496 N2 Metal–protein
Zn2 rPfA-M1 His500 N2 Metal–protein
Zn2 rPfA-M1 Glu519 O1 Metal–protein
Zn2 O3 O3 Metal–ligand
Zn2 O2 O4 Metal–ligand
Protein ligand
Glu319 O1 N2 N H bond
Gly460 N O4 O1 H bond
Ala461 N O4 — H bond
Glu463 O N2/O2 N/O4 H bond
Glu497 O O2/N1 O4 H bond
Tyr580 OH O3 O3 H bond
Water HOH O1 — H bond
Gln317 P1 (Phe) P1 van der Waals
Ala320 — N van der Waals
Val459 O4/O1 P1 van der Waals
Ala461 — C17 van der Waals
Met462 P1 (Phe) P1 van der Waals
Thr492 P1 (Leu) P1 van der Waals
Val493 — P1 van der Waals
Lys518 N2 C19 van der Waals
Tyr575 P1 (Phe) C19 van der Waals
Met1034 P1 (Phe) P1 van der Waals
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